Synthetic biology company programming the next generation of cell therapies
Chicago
Joined March 2026
- Tweets7
- Following32
- Followers11
- Likes14
Syntax Bio retweeted
Syntax Bio expands funding round to $14.4M, reshuffles leadership team chicagobusiness.com/health-c…
Syntax Bio retweeted
Regenerative medicine needs better instructions for cells.
Syntax Bio expanded its Series A to $14.4M, bringing total funding past $25M, as @john_craighead, @RECdomain, Brad Merrill, and Niko Balanis advance Cellgorithm, a CRISPR-based platform that guides pluripotent stem cells through differentiation faster and more consistently.
The next cell therapy winners will not just grow cells. They will program development itself so regenerative medicine can move with greater speed, scale, and precision.
Syntax Bio retweeted
Exciting progress for Syntax Bio: a research and development collaboration with @MayoClinic focused on advancing stem cell-derived pancreatic cell therapies for type 1 diabetes 👏
businesswire.com/news/home/2…